Biomarker and clinical evaluation of bevacizumab (Avastin) to determine the role of nitric oxide in anti-VEGF [vascular epidermal growth factor] therapy.
Phase of Trial: Phase I
Latest Information Update: 09 Jul 2016
At a glance
- Drugs Bevacizumab (Primary)
- Indications Solid tumours
- Focus Biomarker; Pharmacodynamics
- 09 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Feb 2007 New trial record.